Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Public ClinicalTrials.gov record NCT04895410. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Study identification
- NCT ID
- NCT04895410
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- AbbVie
- Industry
- Enrollment
- 8 participants
Conditions and interventions
Conditions
Interventions
- Carfilzomib Drug
- Daratumumab Biological
- Dexamethasone Drug
- Lemzoparlimab Biological
- Pomalidomide Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 16, 2022
- Primary completion
- Jun 23, 2022
- Completion
- Jun 23, 2022
- Last update posted
- Mar 5, 2023
2022
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Sylvester Comprehensive Cancer Center /ID# 228817 | Miami | Florida | 33136-1002 | — |
| Moffitt Cancer Center /ID# 229939 | Tampa | Florida | 33612-9416 | — |
| Norton Cancer Institute - St Matthews /ID# 229319 | Louisville | Kentucky | 40207 | — |
| Tulane Cancer Center Clinic /ID# 229832 | New Orleans | Louisiana | 70112 | — |
| University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 229309 | Ann Arbor | Michigan | 48109 | — |
| Henry Ford Health System /ID# 230341 | Detroit | Michigan | 48202 | — |
| Rutgers Cancer Institute of New Jersey /ID# 230174 | New Brunswick | New Jersey | 08901 | — |
| Columbia University Medical Center /ID# 229971 | New York | New York | 10032-3729 | — |
| Duke University Hospital /ID# 229564 | Durham | North Carolina | 27710 | — |
| Wake Forest Baptist Health /ID# 229996 | Winston-Salem | North Carolina | 27157-0001 | — |
| Perelman Center for Advanced Medicine - /ID# 228693 | Philadelphia | Pennsylvania | 19104-5127 | — |
| University of Virginia /ID# 229396 | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04895410, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2023 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04895410 live on ClinicalTrials.gov.